First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients
Z Hasanshahi, A Hashempour, F Ghasabi… - Bmc …, 2021 - Springer
Abstract Background NS5A and NS5B proteins of hepatitis C virus (HCV) are the main
targets of compounds that directly inhibit HCV infections. However, the emergence of …
targets of compounds that directly inhibit HCV infections. However, the emergence of …
Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance‐associated substitutions in naïve patients from Argentina
AP Martínez, G García, E Ridruejo… - Journal of medical …, 2019 - Wiley Online Library
Direct acting antiviral (DAA) therapy against hepatitis C virus (HCV) increases sustained
virologic response rates. Nevertheless, drug resistance has occasionally been associated …
virologic response rates. Nevertheless, drug resistance has occasionally been associated …
Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b …
A Abergel, T Asselah, A Mallat… - Liver …, 2020 - Wiley Online Library
Background Genotype 1b is the most common HCV genotype worldwide, accounting for the
largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing …
largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing …
Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection
Background Hepatitis C virus (HCV), non-structural 5A (NS5A), and non-structural 5B
(NS5B) resistance-associated substitutions (RASs) are the main causes of failure to direct …
(NS5B) resistance-associated substitutions (RASs) are the main causes of failure to direct …
A short hepatitis C virus NS5A peptide expression by AAV vector modulates human T cell activation and reduces vector immunogenicity
W Colon-Moran, A Baer, G Lamture, JT Stapleton… - Gene therapy, 2022 - nature.com
Viral vector-mediated gene therapies have the potential to treat many human diseases;
however, host immune responses against the vector and/or the transgene pose a safety risk …
however, host immune responses against the vector and/or the transgene pose a safety risk …
Prevalence and factors related to natural resistance-associated substitutions to direct-acting antivirals in patients with genotype 1 hepatitis C virus infection
I Esposito, S Marciano, L Haddad, O Galdame… - Viruses, 2018 - mdpi.com
This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
Genetic diversity of hepatitis C virus and resistance associated substitutions to direct-acting antiviral treatment in Colombia
MC Lopez-Osorio, JA Usme-Ciro, JW Martínez… - Virus Research, 2022 - Elsevier
Hepatitis C virus (HCV) infection is one of the leading risk factors for end-stage liver disease
development worldwide. This RNA virus displays high genetic diversity with 8 genotypes …
development worldwide. This RNA virus displays high genetic diversity with 8 genotypes …
Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients …
APT Santos, VCM Silva, MC Mendes-Corrêa… - Revista do Instituto de …, 2022 - SciELO Brasil
ABSTRACT The Hepatitis C virus (HCV) infection is a public health problem. The high level
of HCV replication and its lack of post-transcriptional correction mechanisms results in the …
of HCV replication and its lack of post-transcriptional correction mechanisms results in the …
Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population
A Ramezani, K Baesi, M Banifazl, M Mohraz… - Clinics and Research in …, 2019 - Elsevier
Background The introduction of direct acting antivirals (DAAs) for hepatitis C virus (HCV)
treatment promises shorter treatment duration, higher cure rates and fewer side effects …
treatment promises shorter treatment duration, higher cure rates and fewer side effects …
[HTML][HTML] The Relationship Between HCV-NS5A Gene Mutations and Resistance to Combination Therapy in Patients with HCV-Genotype 1-B
HE Lashgarian, A Valibeik, A Marzban… - … of Biochemistry & …, 2021 - ncbi.nlm.nih.gov
Background: Hepatitis C virus (HCV) is one of the major causes of chronic liver disease, as it
holds a significant role in developing liver cirrhosis and hepatocellular carcinoma …
holds a significant role in developing liver cirrhosis and hepatocellular carcinoma …